Xcout Intel
Calypso Biotech
Calypso Biotech is a spin-off pharmaceutical company focusing on developing therapeutics for conditions such as celiac disease.
Subscribe to see Calypso Biotech’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Calypso Biotech at a glance
Calypso Biotech is a biotechnology company. It has raised at least $32M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $9.4M in September 2021.
Calypso Biotech funding rounds
At least $32M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $9.4M | 1 named | |
| Series A | $22.6M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Calypso Biotech competitors
A few of Calypso Biotech's closest competitors — see the full list of competitors and alternatives →
Giiant Pharma is a Montreal-based biotechnology company founded by former Merck Frosst scientists with the aim of developing orally-administered, gut-restricted therapeutics.
Calliditas Therapeutics AB is a commercial-stage biopharma company based in Stockholm, Sweden. It focuses on developing and commercializing pharmaceutical products.
Canopy Immuno-Therapeutics is a pre-clinical stage biotechnology company based in Haifa, Israel, focused on developing non-immunosuppressive biologics, including Antigen-Drug Conjugates, for antibody-mediated autoimmune conditions.
Applied Molecular Transport was a United States biotechnology company that developed oral biologic medicines using a proprietary epithelial drug-delivery platform. Its programs targeted gastrointestinal and autoimmune diseases, serving patients with conditions such as inflammatory bowel disease.
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.
Get Calypso Biotech's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Calypso Biotech in Xcout Intel
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access